AU2004270304A1 - Guanidine derivatives - Google Patents

Guanidine derivatives Download PDF

Info

Publication number
AU2004270304A1
AU2004270304A1 AU2004270304A AU2004270304A AU2004270304A1 AU 2004270304 A1 AU2004270304 A1 AU 2004270304A1 AU 2004270304 A AU2004270304 A AU 2004270304A AU 2004270304 A AU2004270304 A AU 2004270304A AU 2004270304 A1 AU2004270304 A1 AU 2004270304A1
Authority
AU
Australia
Prior art keywords
tetrahydro
guanidine
rac
compound
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004270304A
Other languages
English (en)
Inventor
Volker Breu
Anja Fecher
Heinz Fretz
Thomas Giller
Kurt Hilpert
Olivier Valdenaire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AU2004270304A1 publication Critical patent/AU2004270304A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004270304A 2003-09-05 2004-09-03 Guanidine derivatives Abandoned AU2004270304A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1526/03 2003-09-05
CH15262003 2003-09-05
PCT/CH2004/000556 WO2005023781A1 (de) 2003-09-05 2004-09-03 Guanidinderivate

Publications (1)

Publication Number Publication Date
AU2004270304A1 true AU2004270304A1 (en) 2005-03-17

Family

ID=34230846

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004270304A Abandoned AU2004270304A1 (en) 2003-09-05 2004-09-03 Guanidine derivatives

Country Status (16)

Country Link
US (1) US7544691B2 (enExample)
EP (1) EP1663993B1 (enExample)
JP (1) JP2007504176A (enExample)
KR (1) KR20060064065A (enExample)
CN (1) CN1845907B (enExample)
AT (1) ATE388943T1 (enExample)
AU (1) AU2004270304A1 (enExample)
BR (1) BRPI0414103A (enExample)
CA (1) CA2536927A1 (enExample)
DE (1) DE502004006515D1 (enExample)
ES (1) ES2300807T3 (enExample)
IL (1) IL173853A0 (enExample)
NO (1) NO20061531L (enExample)
PL (1) PL1663993T3 (enExample)
RU (1) RU2006110738A (enExample)
WO (1) WO2005023781A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
ES2708552T3 (es) 2002-12-20 2019-04-10 Niconovum Ab Método para la preparación de un material particulado que contiene nicotina con una celulosa cristalina (en particular MCC)
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
CN102665406B (zh) * 2009-12-24 2016-03-09 诺沃梅尔公司 合成多环胍化合物的方法
WO2015002150A1 (ja) 2013-07-03 2015-01-08 株式会社新日本科学 新規化合物，有機カチオントランスポーター３の検出剤及び活性阻害剤
WO2018152134A1 (en) 2017-02-14 2018-08-23 Research Triangle Institute Proline-based neuropeptide ff receptor modulators
CN108159032A (zh) * 2018-01-24 2018-06-15 昆明理工大学 二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法
CN108159031A (zh) * 2018-01-24 2018-06-15 昆明理工大学 二甲双胍在制备预防和/或治疗苯丙胺类毒品成瘾药物中的应用和药物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505327A (en) 1967-08-07 1970-04-07 American Cyanamid Co Tetrahydroquinoxalinyl phosphates or thiophosphates
BE795257A (fr) 1972-02-10 1973-08-09 Thomae Gmbh Dr K Nouveaux oxazols
DE3334455A1 (de) * 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen Guanidin - derivate
WO2003026667A1 (en) * 2001-09-24 2003-04-03 Synaptic Pharmaceutical Corporation Quinazolino- and quinolino- guanidines as ligands for the neurop eptide ff (npff) receptors
WO2003026657A1 (en) * 2001-09-24 2003-04-03 Synaptic Pharmaceutical Corporation Compounds for the treatment of pain
US20030139431A1 (en) * 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors

Also Published As

Publication number Publication date
CN1845907A (zh) 2006-10-11
WO2005023781A1 (de) 2005-03-17
CN1845907B (zh) 2010-07-28
NO20061531L (no) 2006-04-04
DE502004006515D1 (en) 2008-04-24
JP2007504176A (ja) 2007-03-01
RU2006110738A (ru) 2007-12-10
PL1663993T3 (pl) 2008-08-29
IL173853A0 (en) 2006-07-05
US20070123510A1 (en) 2007-05-31
ATE388943T1 (de) 2008-03-15
CA2536927A1 (en) 2005-03-17
EP1663993A1 (de) 2006-06-07
US7544691B2 (en) 2009-06-09
ES2300807T3 (es) 2008-06-16
BRPI0414103A (pt) 2006-10-31
EP1663993B1 (de) 2008-03-12
KR20060064065A (ko) 2006-06-12

Similar Documents

Publication Publication Date Title
US8309561B2 (en) Phenylalanine derivatives
CN110913855B (zh) 含咪唑的alk2激酶抑制剂
KR0133372B1 (ko) 4-아미노(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
US20030104974A1 (en) Dual inhibitorsof PDE 7 and PDE 4
US20060148838A1 (en) Novel pyrrolodihydroisoquinolines useful in the treatment of cancer
NZ581936A (en) Bicycloaniline derivatives
MXPA05000814A (es) Inhibidores de quinasas.
JP2022524456A (ja) Ｈｂｖ感染又はｈｂｖ誘導性疾患の治療における使用のための縮合環ピリミドン誘導体
WO2007056215A2 (en) N-aryl-thienopyrimidin-4-amines and the use thereof
CN104936962B (zh) 治疗活性的噁唑啉衍生物
US20080113946A1 (en) N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2004270304A1 (en) Guanidine derivatives
AU2012271661A1 (en) Cycloalkyl-fused tetrahydroquinolines as CRTH2 receptor modulators
CN113747894B (zh) 成纤维细胞生长因子受体2(fgfr2)的降解剂
WO2009154870A1 (en) Hiv integrase inhibitors
CA2577879A1 (en) Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i.epsilon.
JP2007504176A5 (enExample)
CA1331177C (en) 3-oxo-1,2,4-triazolo[4,3-a]pyrimidine-6-carboxylic acid esters
EP0623620B1 (fr) Dérivés de pyrrolopyrazines à activité 5-HT3
AU2023361063A1 (en) Novel tricyclic derivative compound and uses thereof
NO327260B1 (no) Optisk rene camptothecin-analoger, medikament og farmasoytisk preparat inneholdende slike forbindelser samt anvendelse av slike forbindelser for fremstilling av medikament for behandling av sykdom
WO2023029943A1 (zh) 一种芳杂环化合物及其制备方法和用途
JP2022535496A (ja) Ｕｓｐ１９の抑制
KR20160079896A (ko) 단백질 키나제 저해제
KR20250175338A (ko) Tyk2 분해제 및 이의 용도

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application